Radioimmunodetection and Radiotherapy with Radiolabelled Antibodies

摘要

The focus of the Symposium was on basic problems which can interfer with clinical applications of monoclonal antibodies. The importance of technical factors in both producing the antibodies, and in subsequently radiolabeling these antibody preparations were discussed. Throughout all of these preparatory steps, it is important to keep in mind that the immunoactivity of the antibody must be retained at all costs. The importance of developing new methods which would allow for larger amounts of specific high quality antibody to the prepared were stressed. The importance of this was emphasized in that dose parameters and dose studies currently underway at the time of the meeting, indicated that larger doses of Fab were more effective in targeting tumor than smaller doses. All of the participants agreed that the potential applicability of this technique was very great. Highly tumor-specific monoclonal antibodies have been developed against virtually all the common solid tumors of major clinical importance in man. These include colon, breast, lung, and melanoma. Prostate and lymphatic tissue, also had specific antibodies developed against them. A major factor in determining the success of this technique in the future will be overcoming important technical barriers to the targeting of these radiolabeled antibodies to tumors. These barriers include the difficulty in producing large quantities of radiolabeled immunoactive antibodies. (ERA citation 11:017437)